| Revenue growth | 16% YoY growth recorded this quarter. |
|---|---|
| Margins | Margins currently muted (24.8%) due to expansion and M&A costs. |
| Demand visibility | Strong; 75% Network occupancy despite 13% capacity increase. |
| Management confidence | High; citing success in brownfield ramp-ups and turnaround of acquisitions. |
Growth
Revenue and operating EBITDA saw 16% and 15% YoY growth respectively. PAT stood at INR 357 Cr.
Outlook
Capex of INR 425 Cr approved for Vaishali tower; 100 beds in Lucknow and 500 in Gurgaon upcoming.
Risks
EBITDA margins muted at 24.8% due to new capacity commissioning and acquisition integration; Oncology revenue share dropped.
Last quarter's promises, checked
Delivered
- Lucknow capacity increase to 570 beds → delivered 570 beds (= BEAT)
- Kalinga Hospital integration from Q1 FY27 → delivered integrated status (= BEAT)
- Maintain Net Debt-to-EBITDA < 1.0x → delivered 0.85x (= BEAT)
Partly delivered
- EBITDA per bed INR 73L → delivered INR 72L (= PARTIAL)
- Gurgaon 500-bed commissioning by end of year → project on track but pending (= PARTIAL)
Missed
- Onco share to hover 21-22% → delivered 19% (= MISS)
Earnings Call Transcript filed with BSE, NSE: MAXHEALTH. Summary written with AI assistance from the document.
Max Healthcare Institute Ltd: key numbers
- Share price
- ₹1,014.00
- Market cap
- ₹98,694 Cr
- Revenue (annual)
- ₹8,373 Cr
- Net profit (annual)
- ₹1,442 Cr
- P/E (TTM)
- 67.7×Sector 57.8×
- Promoter holding
- 23.71%+0.00% QoQ
- FII holding
- 41.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Max Healthcare Institute Ltd
All →Max Healthcare Institute Annual General Meeting
Max Healthcare Institute Ltd issued a postal ballot notice to seek shareholder approval for its 2026 ESOP scheme, director remuneration, and alterations to its objects clause.
Max Healthcare Institute Other Announcement
Max Healthcare has received an ESG rating of '72' from Niche99, a SEBI-registered provider. This independent rating places the company in the 'Leader' category.
Max Healthcare Institute Legal & Regulatory
Max Healthcare disclosed an update on ongoing NCLT proceedings initiated by BRS Capital against its subsidiary. The next hearing is scheduled for September 28, 2026.
Max Healthcare Institute Employee Stock Options
Max Healthcare Institute Limited has allotted 33,765 equity shares under its ESOP scheme. This increases the total paid-up share capital to 973,310,251 equity shares.
Max Healthcare Institute Employee Stock Options
Max Healthcare allotted 33,765 equity shares under its Employee Stock Option Scheme 2022. The allotment was made at an exercise price of ₹350 per share.
- Value
- ₹1.18 Cr
Max Healthcare Institute Acquisition Worth ₹87.87 Cr
Max Healthcare Institute Limited approved an additional investment of Rs. 87.87 Crore in its subsidiary, Kalinga Hospital Limited. The funds will support capital expenditure and modernization programs.
- Value
- ₹87.87 Cr
- Execution
- Within next 15 days